Brian Abrahams

Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish

Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug

Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target

Why Neumora Therapeutics Analysts Are Bullish About Major Depressive Disorder Drug

Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

7 Biogen Analysts On Alzheimer's Drug Success As Stock Skyrockets 37%

Why This Analyst Sees Roughly 20% Upside In This Large-Cap Biopharma

4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize

Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone

Brian Abrahams Recent News

Sage's First-Of-Its-Kind Postpartum Depression Drug Clears FDA Hurdle: What You Need to Know

RBC Downgrades Intercept Pharma On Valuation, Remains Positive On Upcoming Trial Data

Inspired By Tesla: RBC Speculates On Go-Private Scenario For Celgene

After Biogen's Alzheimer's Update, Wall Street Reacts

Incyte Downgraded As RBC Analyst Awaits More Revenue Visbility

Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'

More Data Needed On Proteostasis Therapeutics' Cystic Fibrosis Candidate, RBC Says In Downgrade

Sage Therapeutics Could Still Become A Leader In Neurology

Your Cheat Sheet For Q1 Biotech Earnings

Jefferies' Picks For 2017's Most And Least Likely Biotech M&A Targets

Gilead Sciences Price Target Trimmed Following A Sobering Q3

Jefferies Says Gilead's 4997 Data Is Impressive, Underappreciated

Biogen Downgraded To Hold At Jefferies, Citing Valuation

Jefferies Upgrades Gilead To Buy Citing Bullish Prospects For HIV Franchise

Jefferies Upgrades Karyopharm To Buy As STORM Data Likely To Predict Sunny Skies

Jefferies Ponders Whether Gilead Sciences Should Experiment With An HCV Spinoff

Celgene's Phase 3 Study Of REMARC Likely To Be Successful, Says Jefferies

Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold

Mirati Therapeutics Shares Plunge 40%; Jefferies Downgrades To Hold

Gilead's 'R&D Day' Points To Upside For Shareholders

Biotech Investors Still Have Opportunity

Achillion Pharmaceuticals, Inc. Less Attractive Amid Johnson & Johnson/Alios BioPharma Deal

Two Analysts Don't See Celgene's Weak Trial Results As A Huge Setback